Clinical Trials Logo

Clinical Trial Summary

Creation of a patient library in Medically Assisted Procreation to allow the implementation of further research with the following objectives: - To identify new relevant biomarkers in patients who will carry a pregnancy to term - To better specify or identify new infertility risk factors - To identify new relevant biomarkers in patients with reduced ovarian reserve Four consultations are planned with biological et clinical collection.


Clinical Trial Description

- A first initial consultation for prescription of the infertility assessment, - a consultation 2 summarizing the examinations and delivery of prescriptions - a blood sample: basal hormonal assessment with AMH (Anti-Mullerian Hormone), - a urine sample to look for an infection with Chlamydia Trachomatis, which is one of the bacteria responsible for gynecological infections compromising ART. - an HPV (Human Papillomavirus) test on vaginal swab - a consultation 3 corresponding to the start of a treatment cycle for IVF with oocyte retrieval at the end of this treatment cycle. - A consultation lasting 4 to 4-6 weeks to take stock of the success or failure of the ART. - A pregnancy follow-up consultation if successful, for a pelvic ultrasound, then monthly pregnancy follow-up (one consultation per month). - As part of the usual ART monitoring, clinical and paraclinical data are collected using the MEDIFIRST software. - During the inclusion visit, questionnaire => will be completed over an additional time to the consultation if inclusion is desired, inclusion time provided by one of the doctors participating in the study. For the FERTITHEQUE, will be collected: - clinical characteristics collected at each consultation as part of the usual follow-up. - biological characteristics measured as part of the usual follow-up. - During consultation 2, during a blood test carried out as part of your usual care, additional tubes will be taken (4 to 5 tubes of 10mL) to carry out the banking of DNA (support of genetic information), plasma (plasma library), serum (serotheque). - During consultation 2, a swab will also be taken from the vaginal microbiota. - During consultation 3, a conservation of the follicular fluid (puncture fluid) will be carried out. - During consultation 4, a plasma library will be performed again, whether there is pregnancy or not, as well as a new swab sample for the vaginal microbiota. Then, as described above, patients are after inclusion as part of the usual IVF follow-up reviewed at 1 month for oocyte retrieval then at 2 months for the follow-up visit allowing observation of success or failure of the treatment cycle. - If pregnancy is achieved, patients are seen monthly as part of their usual follow-up until delivery. - If a pregnancy is not achieved, follow-up stops. - Whether or not a pregnancy is obtained, during the visit at 2 months (V4), a plasma library and a vaginal microbiota are again performed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05599724
Study type Observational [Patient Registry]
Source University Hospital, Brest
Contact Sarah BOUEE
Phone +33 02 98 22 32 22
Email sarah.bouee@chu-brest.fr
Status Recruiting
Phase
Start date November 11, 2022
Completion date August 15, 2028

See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A